Jeff Martin
Stock Analyst at Roth Capital
(3.43)
# 943
Out of 5,050 analysts
62
Total ratings
58.73%
Success rate
14.91%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSP Insperity | Maintains: Buy | $85 → $74 | $33.86 | +118.55% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $14.89 | +81.33% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $4.31 | +16.14% | 1 | May 14, 2025 | |
| PERI Perion Network | Upgrades: Buy | $9 → $14 | $8.97 | +56.08% | 9 | May 14, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $224 → $245 | $284.86 | -13.99% | 16 | May 2, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $3.54 | +154.24% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $33.31 | +35.09% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $18.57 | +61.55% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $32.54 | +32.15% | 5 | Aug 8, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.21 | +477,908.30% | 2 | Nov 15, 2017 |
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $33.86
Upside: +118.55%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $14.89
Upside: +81.33%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $4.31
Upside: +16.14%
Perion Network
May 14, 2025
Upgrades: Buy
Price Target: $9 → $14
Current: $8.97
Upside: +56.08%
OSI Systems
May 2, 2025
Maintains: Buy
Price Target: $224 → $245
Current: $284.86
Upside: -13.99%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.54
Upside: +154.24%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $33.31
Upside: +35.09%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $18.57
Upside: +61.55%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $32.54
Upside: +32.15%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.21
Upside: +477,908.30%